Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study
Authors' conclusion
In this contemporary STEMI population, high Lp(a) levels were linked to an increased MACE risk, and very high Lp(a) levels (≥ 50 mg/dL) significantly indicated poor outcomes in patients with DM, while not for those without DM.
Study context
- Population
- Chinese patients with STEMI who underwent emergency percutaneous coronary intervention (PCI), March 2017–January 2020
- Participants
- 1,543 patients
- Exposure
- Lp levels by diabetes mellitus (DM) status
- Outcome
- MACE: composite of all-cause death, MI recurrence and stroke
- Follow-up
- 1446-day follow-up
Main finding
As reported in the abstract
MACE by Lp(a) level, within DM and nonDM subgroups
Adjusted hazard ratio (95% CI)P value
DM, Lp(a) ≥ 50 mg/dLvs DM, Lp(a) < 10 mg/dL
1.85(1.10–3.11)
P = 0.021nonDM, Lp(a) ≥ 50 mg/dLvs nonDM, Lp(a) < 10 mg/dL
0.57(0.32–1.05)
P = 0.071Observational data: associations, not effects.
Further findings
MACE overall and by DM status · 1446-day follow-up
| Outcome | Fold risk (95% CI) | P value |
|---|---|---|
| MACE by combined DM status and Lp(a) 30 mg/dL cut-offnonDM, Lp(a) < 30 mg/dL vs nonDM, Lp(a) ≥ 30 mg/dL | 1.67 (1.11–2.50) | P = 0.013 |
| MACE by combined DM status and Lp(a) 30 mg/dL cut-offDM, Lp(a) < 30 mg/dL vs nonDM, Lp(a) ≥ 30 mg/dL | 1.53 (1.02–2.31) | P = 0.041 |
| MACE by combined DM status and Lp(a) 30 mg/dL cut-offDM, Lp(a) ≥ 30 mg/dL vs nonDM, Lp(a) ≥ 30 mg/dL | 2.08 (1.33–3.26) | P = 0.001 |
- Major adverse cardiovascular events (MACE) overall and by DM status — MACE overall
- 275 patients (17.8%)
Original publication
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study. Cardiovasc Diabetol. Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →